In the News

Marisa Pearce at Molecular MD, an ICON company, argues that, although immunotherapy is nothing new, it has much untapped potential yet to be explored.

Learn how the use of technology has become ubiquitous in clinical trials as the industry looks to streamline and improve processes.

ACT approaches have the possibilities of therapies with reduced safety concerns, a higher therapeutic index, as well as breadth of targets including solid tumours. More details here.

PharmaVOICE article featuring commentary from E.B. McLindon on the increasing complexity of protocol design & the importance of assessing patient & site burden.

Matthew McCarty at ICON establishes a greater unified approach to patient engagement, retention, and compliance through patient-facing technologies.

ICON has acquired a majority shareholding in MeDiNova Research, a site network with research sites in Europe and Africa.

In this Clinical Informatics News article, featuring commentary from ICON's Marie McCarthy, leveraging technology to accelerate study close-out is discussed.

PharmaVOICE presents a podcast featuring ICON expert Marie McCarthy & Chen Admati (Intel), discussing the use of emerging tech to improve the efficiency of R&D.

An Outsourcing Pharma article featuring commentary from EB McLindon & Gretchen Goller, on ICON’s new web-based patient engagement platform.

There has been growing interest among politicians & the public for significant change of the US healthcare system.